Web Results

en.wikipedia.org/wiki/Takeda_Pharmaceutical_Company

On 30 September 2014, Takeda announced its intention to expand a collaboration with MacroGenics, valued up to USD1.6 billion. The collaboration will focus on the co-development of the preclinical autoimmune compound MGD010. MGD010 is a therapy which targets the B-cell surface proteins CD32B and CD79B, and is ...

www.takeda.com/what-we-do/research-and-development

Our Research. Innovation is at the heart of our R&D. Our researchers and scientists are striving to bring scientific breakthroughs from the lab to patients worldwide. Takeda R&D continues its transformation, driving our patient-centric approach and commitment to deliver innovation. We innovate with focus on three  ...

www.takeda.us/research_development

As a research-based pharmaceutical company, efforts are currently focused on pre-clinical work and clinical development activities in the Americas. Takeda Development Center Americas, Inc. works closely with Takeda's research, development and commercialization entities worldwide to transform discoveries into ...

www.takeda.us

Takeda's U.S. clinical development activities are conducted via Takeda Development Center Americas, Inc., which has a robust pipeline of compounds in multiple therapeutic areas including metabolic and cardiovascular diseases, central nervous system, respiratory and immunology, oncology and general medicine.

www.takeda.us/newsroom/press_release_detail.aspx?id=40

Jan 6, 2004 ... Lincolnshire, Ill., January 6, 2004 – Takeda Pharmaceuticals North America, Inc. ( TPNA) announced the establishment of its new wholly owned subsidiary – the Takeda Global Research & Development Center, Inc. (TGRD). The new organization, to be located on TPNA's campus in Lincolnshire, Ill., will ...

www.takeda.us/about_takeda

It is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company and one with a 230-year heritage. Takeda's U.S. clinical development activities are conducted via Takeda Development Center Americas, Inc. The respective companies currently market metabolic and ...

www.takeda.us/newsroom/press_release_detail.aspx?id=293

Nov 14, 2013 ... As a science and evidence-based company with a strong presence in Deerfield, Ill., Takeda is committed to contributing to the health of people worldwide and supporting the community and the environment. Takeda Pharmaceuticals U.S.A., Inc., and Takeda Development Center Americas, Inc. are ...

www.takeda.us/newsroom/press_release_detail.aspx?id=127

Mar 31, 2009 ... Nancy Joseph-Ridge, M.D., will replace Dr. Masaomi Miyamoto as General Manager, Pharmaceutical Development Division. Dr. Joseph-Ridge is currently President of Takeda Global Research & Development Center, Inc., U.S., and will retain this position until her replacement has been announced.

www.linkedin.com/company/takeda-pharmaceuticals

For more than 230 years, Takeda has brought hope to people around the world through our people-centered and innovation-driven approach to science and medicine. As a global pharmaceutical leader, we focus on solving unmet needs where we can make a real difference—and on putting patients first. Our therapeutics ...